TruTag: Development of a Silica Microparticle Taggant System to Measure Antiretroviral Pharmacotherapy Adherence

2024p001248

Developing technologies to help measure and provide tools to support medication-taking behaviors (medication adherence) is an important step to ending the human immunodeficiency virus (HIV) epidemic. TruTag Technologies has pioneered the use of a microparticle system that can be incorporated into the coating of medications may help users both identify the medication they are taking and record adherence events. By using a standard smartphone camera, shining light on TruTag-coated medications automatically identifies them to an onboard smartphone app which then indirectly records the adherence event. This study evaluates the real-world usability and feasibility of operating this system among people living with HIV (PLWH).

2024-07-01

2024-12-30

2025-04-15

Not yet recruiting

15

Inclusion Criteria: 1. Age 18 or older 2. Living with HIV 3. Currently prescribed and taking Biktarvy as ART for at least 3 months 4. Undetectable viral load in prior 6 months 5. Owns iPhone model 11 or higher (non-SE only) Exclusion Criteria: 1. Not English-speaking 2. Unwilling to interact with the TruTag app

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Single arm pilot demonstration', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 15, 'type': 'ESTIMATED'}}

2024-06-19